PreprintReviewVersion 1Preserved in Portico This version is not peer-reviewed
The Potential Use of Soluble TREM Like Transcript – 1, a Platelet-Specific Receptor, for Early Detection of Anthracyclines Induced Congestive Heart Failure (CHF) in Leukemia Patients
Version 1
: Received: 7 February 2024 / Approved: 7 February 2024 / Online: 7 February 2024 (17:08:39 CET)
How to cite:
Branfield, S.; LaGrand, S.; Cleary, I.; Gibson, A.; Washington, A. V. The Potential Use of Soluble TREM Like Transcript – 1, a Platelet-Specific Receptor, for Early Detection of Anthracyclines Induced Congestive Heart Failure (CHF) in Leukemia Patients. Preprints2024, 2024020456. https://doi.org/10.20944/preprints202402.0456.v1
Branfield, S.; LaGrand, S.; Cleary, I.; Gibson, A.; Washington, A. V. The Potential Use of Soluble TREM Like Transcript – 1, a Platelet-Specific Receptor, for Early Detection of Anthracyclines Induced Congestive Heart Failure (CHF) in Leukemia Patients. Preprints 2024, 2024020456. https://doi.org/10.20944/preprints202402.0456.v1
Branfield, S.; LaGrand, S.; Cleary, I.; Gibson, A.; Washington, A. V. The Potential Use of Soluble TREM Like Transcript – 1, a Platelet-Specific Receptor, for Early Detection of Anthracyclines Induced Congestive Heart Failure (CHF) in Leukemia Patients. Preprints2024, 2024020456. https://doi.org/10.20944/preprints202402.0456.v1
APA Style
Branfield, S., LaGrand, S., Cleary, I., Gibson, A., & Washington, A. V. (2024). The Potential Use of Soluble TREM Like Transcript – 1, a Platelet-Specific Receptor, for Early Detection of Anthracyclines Induced Congestive Heart Failure (CHF) in Leukemia Patients. Preprints. https://doi.org/10.20944/preprints202402.0456.v1
Chicago/Turabian Style
Branfield, S., Angelia Gibson and Anthony Valance Washington. 2024 "The Potential Use of Soluble TREM Like Transcript – 1, a Platelet-Specific Receptor, for Early Detection of Anthracyclines Induced Congestive Heart Failure (CHF) in Leukemia Patients" Preprints. https://doi.org/10.20944/preprints202402.0456.v1
Abstract
Leukemia, contributing to 3% of all cancer cases in the United States, presents a significant challenge in treatment due to its diverse subtypes, each dis-playing unique genetic and molecular abnormalities. The aggressive growth of ab-normal blood cells compromises immune function and poses challenges in developing effective therapeutic approaches. Unlike solid tumors, surgical resection is not an option, limiting treatment strategies to chemotherapy, immunotherapy, and radiation therapy, which may be nonspecific and lead to organ damage and toxicity.
Anthracyclines, widely used in hematological tumors, face limitations due to severe cardiotoxicity, causing progressive cardiomyopathy and, in severe cases, congestive heart failure. Heart failure incidence is significantly higher in cancer patients treated with anthracyclines over 5, 10, and 15 years. Early detection of left ventricular dysfunction and cardiotoxicity is crucial to mitigate progression to congestive heart failure (CHF) in this population.
Recent research by Bayrón-Marrero et al. reveals that lower levels of plasma soluble TREM-Like Transcript-1 (s-TLT-1), a platelet-specific receptor, correlate with left ven-tricular dysfunction in cardiovascular disease patients. Those with s-TLT-1 levels ex-ceeding 544 pg/mL exhibit a significant association with congestive heart failure. These findings suggest the potential use of s-TLT-1 as a diagnostic screening tool for early detection and treatment of anthracycline-induced CHF in leukemia patients.
Keywords
Keywords: keyword triggering receptor expressed in myeloid cells-like transcript (TLT-1); blood platelets; cardiovascular diseases; left ventricular ejection fraction (LVEF); biomarker; anthracyclines, Troponin I, cardiotoxicity, congestive heart failure (CHF)
Subject
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.